Korea Biomedical Review

Seoul, South Korea Founded: 2017 • Age: 9 yrs Acquired
Biomedical review information is provided via an online platform.

About Korea Biomedical Review

Korea Biomedical Review is a Media & Entertainment company based in Seoul (South Korea) founded in 2017. Biomedical review information is provided via an online platform. It operates on a Advertising Model model. Its chief executive, as recorded, is Yang Kyung Cheol. Its website koreabiomed.com draws about 63 thousand monthly visits. The company has since been acquired. Korea Biomedical Review offers products and services including KBR Online News Platform. Its focus areas include Media, Digital Media and Online News. Its legal entity is The Korean Doctors’ Weekly Co., Ltd.

Company details

Korea Biomedical Review is managed as a leading online news platform in South Korea, dedicated to the biomedical and healthcare industries. Coverage is provided across pharmaceuticals, biotechnology, medical devices, ICT, beauty, policy, hospitals, and life sciences. Detailed reporting is offered on industry trends, innovations, and regulatory updates. The platform serves as a key resource for professionals and stakeholders in the Korean and global healthcare markets. Content is curated to ensure timely and accurate information is disseminated to its audience.

  • Headquarters Seoul, South Korea
  • Stage Acquired
  • Sectors
    Media & Entertainment
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website koreabiomed.com
  • Social LinkedIn X Facebook
  • Legal Name The Korean Doctors’ Weekly Co., Ltd
Key Metrics

Products & Services of Korea Biomedical Review

Korea Biomedical Review offers a comprehensive portfolio of products and services, including KBR Online News Platform.

KBR Online News Platform
Media

Online news platform covering biomedical industry updates.

Investors in Korea Biomedical Review

Korea Biomedical Review has secured backing from 1 investor. Prominent investors backing the company include Dx&Vx.

All
InvestorDescriptionFounded YearDomainLocation
No company activity is described on the website.
dxvx.com
Premium access

Investor details for Korea Biomedical Review

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Korea Biomedical Review

3 people are tracked at Korea Biomedical Review (3 in leadership).

NameRoleGroup
shim Hyun-tai
Leadership
Yang Kyung Cheol
CEOLeadership
Kim Chan-hyuk
News AuthorLeadership
Premium access

Complete people profiles for Korea Biomedical Review

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Web traffic of Korea Biomedical Review

The website of Korea Biomedical Review (koreabiomed.com) receives about 62.6K visits a month.

  • Monthly visits
    62.6K

    ▲ 27.4% vs previous month

Similar websites

Websites whose visitors overlap most with Korea Biomedical Review. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
medicaldialogues.in
100%
1.5M#49,047View details
firstwordpharma.com
firstwordpharma.com
99%
#237,108–
ivxhealth.com
89%
33.4K#903,729View details
vax-before-travel.com
vax-before-travel.com
82%
#467,958–
pharmacytimes.com
82%
495.5K#125,424View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Korea Biomedical Review

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Korea Biomedical Review

Korea Biomedical Review was founded in 2017.

Korea Biomedical Review is headquartered in Seoul, South Korea.

Yang Kyung Cheol is the CEO of Korea Biomedical Review, as recorded in our data.

Korea Biomedical Review is managed as a leading online news platform in South Korea, dedicated to the biomedical and healthcare industries. Coverage is provided across pharmaceuticals, biotechnology, medical devices, ICT, beauty, policy, hospitals, and life sciences. Detailed reporting is offered on industry trends, innovations, and regulatory updates. The platform serves as a key resource for professionals and stakeholders in the Korean and global healthcare markets. Content is curated to ensure timely and accurate information is disseminated to its audience.

Korea Biomedical Review offers KBR Online News Platform.

Korea Biomedical Review has 1 investor. Key investors include Dx&Vx.

Korea Biomedical Review operates through The Korean Doctors’ Weekly Co., Ltd.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available